Tandem Diabetes Care Announces Launch of t:lock Connector for its Insulin Pump Cartridges and Infusion Sets
August 23 2017 - 8:30AM
Business Wire
Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device
company and manufacturer of the only touchscreen insulin pumps
available in the United States, today announced the launch of the
t:lock™ Connector for its insulin pump cartridges and infusion
sets. All of the infusion sets currently offered by the Company
will be made available with the new t:lock Connector, produced and
supplied by Unomedical a/s, a ConvaTec Group Plc company.
The t:lock Connector was designed to look and feel like the
previous Luer-lock connector, while improving the customer
experience of filling an infusion set with insulin. The Connector
incorporates a smaller inner cavity, which reduces the amount of
insulin used in the process and reduces the time required to fill
the infusion set tubing.
“This launch strengthens our overall insulin delivery systems,
addressing one of our customers’ most frequent requests to make the
infusion set fill process more efficient,” said Kim Blickenstaff,
President and CEO of Tandem Diabetes Care. “We continue to invest
in ways to improve our products and deliver new technology, as part
of our overall mission to provide innovative solutions to help
improve the lives of people with diabetes.”
“We are excited to further our current partnership with Tandem
Diabetes Care with the implementation of their optimized t:lock
Connector,” said John M. Lindskog, President of ConvaTec Infusion
Devices (Unomedical). “The available t:lock line of infusion sets
offers a variety of solutions for their customers, and we look
forward to working with Tandem to further expand their offerings in
the future.”
Unomedical manufactures Tandem’s existing sets as well as many
of the most popular private-labeled infusion sets of major insulin
pump manufacturers under their respective brand names. The t:lock
versions of Tandem’s current infusion sets will be sold under the
brand names AutoSoft™, VariSoft™ and TruSteel™. Tandem will conduct
a gradual rollout of its t:lock Connector to all customers and
distributors beginning September 5, 2017 and anticipates fully
transitioning by the end of 2017.
Information for Current Tandem CustomersNo action is
required by Tandem customers at this time. Tandem and its
authorized distributors will work with customers to provide current
Luer-lock versions of infusion sets and cartridges that are
compatible with supplies they have on hand before transitioning to
the t:lock Connector cartridges and infusion sets (while supplies
last). Only t:lock Connector infusion sets will work with the new
t:lock Connector cartridges. Infusion sets and cartridges featuring
the t:lock Connector will have the same insurance coverage as
current supplies.
For more information on the t:lock Connector, please visit
www.tandemdiabetes.com/tlock.
About Tandem Diabetes Care, Inc.Tandem Diabetes Care,
Inc. (www.tandemdiabetes.com) is a medical device company with an
innovative, user-centric and integrated approach to the design,
development and commercialization of products for people with
diabetes who use insulin. The Company manufactures and sells the
t:slim X2™ Insulin Pump, the slimmest and smallest durable insulin
pump currently on the market, the t:flex® Insulin Pump, the first
pump designed for people with greater insulin requirements, and the
t:slim G4™ Insulin Pump, the first continuous glucose
monitoring-enabled pump with touchscreen simplicity. Tandem is
based in San Diego, California.
Follow Tandem Diabetes Care on Twitter @tandemdiabetes; use
#tslimX2, #tslimG4, #tflex, #tconnect, and $TNDM.Follow Tandem
Diabetes Care on Facebook at www.facebook.com/TandemDiabetes.Follow
Tandem Diabetes Care on LinkedIn at
https://www.linkedin.com/company/tandemdiabetes.
t:slim, t:flex, and Tandem Diabetes Care are registered
trademarks, and t:slim X2, t:slim G4 and t:lock are trademarks of
Tandem Diabetes Care, Inc. All other trademarks are the property of
their respective owners.
Forward Looking StatementThis press release contains
“forward-looking statements” within the meaning of Section 27A
of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended, that concern
matters that involve risks and uncertainties that could cause
actual results to differ materially from those anticipated or
projected in the forward-looking statements. These
forward-looking statements include statements regarding the timing
of the rollout of the t:lock Connector and the Company’s
expectations that the t:lock Connector will make the infusion set
fill process more efficient. The Company's actual results may
differ materially from those indicated in these forward-looking
statements due to numerous risks and uncertainties. For instance,
the Company may be unable to manufacture infusion sets with the
t:lock connector at volumes necessary to support the needs of its
existing and future customers, the anticipated rollout period may
take longer than anticipated, and the Company may not ultimately be
able to gain market acceptance for the t:lock Connector. In
addition, the Company’s results may be impacted by the other risks
identified in the Company’s most recent Annual Report on Form 10-K,
Quarterly Report on Form 10-Q, and other documents that the Company
files with the Securities and Exchange Commission. Investors are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this release. Tandem
undertakes no obligation to update or review any forward-looking
statement in this press release because of new information, future
events or other factors.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170823005171/en/
Tandem Diabetes Care, Inc.Media Contact:Steve
Sabicer, 714-907-6264ssabicer@thesabicergroup.comorInvestor
Contact:Susan Morrison, 858-366-6900
x7005smorrison@tandemdiabetes.com
Tandem Diabetes Care (NASDAQ:TNDM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Tandem Diabetes Care (NASDAQ:TNDM)
Historical Stock Chart
From Apr 2023 to Apr 2024